Mode
Text Size
Log in / Sign up
Phase 1 N=18 Other

Tepotinib Hepatic Impairment Trial

Hepatic Impairment

Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Aug 2024
Primary outcome: Primary: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity ( AUC0-inf ) of Tepotinib — 27500; 26100; 24200 Nanogram*hour per milliliter (ng*h/mL)

Study Design & Population

Study type
Interventional
Phase
Phase 1
Interventions
Tepotinib (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
EMD Serono Research & Development Institute, Inc.
Primary completion
Feb 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Area Under the Plasma Concentration Time Curve From Time Zero to Infinity ( AUC0-inf ) of Tepotinib
27500; 26100; 24200
PRIMARY
Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Tepotinib
27000; 25600; 23500
PRIMARY
Maximum Observed Plasma Concentration (Cmax) of Tepotinib
406; 416; 288
SECONDARY
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Tepotinib
11; 11.00; 16.00
SECONDARY
Apparent Terminal Half Life (t1/2) of Tepotinib
36.8; 43.7; 46.1
SECONDARY
Apparent Total Body Clearance (CL/f) of Tepotinib
16.4; 17.2; 18.6
SECONDARY
Apparent Volume of Distribution During Terminal Phase (VZ/f) of Tepotinib
892; 1050; 1400
SECONDARY
Extrapolated Area Under the Plasma Concentration-Time Curve From Time t to Infinity as a Percentage of AUC0-Inf (AUCextra) of Tepotinib
1.34; 5.01; 3.35; 1.06; 0.895; 3.03
SECONDARY
Extrapolated Area Under the Plasma Concentration-Time Curve From Time t to Infinity as a Percentage of AUC0-Inf (AUCextra) of Tepotinib Metabolite (MSC2571109)
0.799; 1.44; 2.05; 1.28; 0.574; 1.41
SECONDARY
Extrapolated Area Under the Plasma Concentration-Time Curve From Time t to Infinity as a Percentage of AUC0-Inf (AUCextra) of Tepotinib Metabolite (MSC2571107)
0.592; 3.69; 2.10; 0.925; 0.848; 5.68
SECONDARY
Area Under the Plasma Concentration Time Curve for Unbound Drug From Time Zero (Dosing Time) Extrapolated to Infinity (AUC0-inf, u) of Tepotinib
532; 585; 653
SECONDARY
Maximum Observed Unbound Plasma Concentration (Cmax,u) of Tepotinib
7.87; 9.32; 7.80
SECONDARY
Apparent Total Body Clearance of Unbound Drug Following Extravascular Administration (CL/f,u) of Tepotinib
845; 770; 689
SECONDARY
Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Tepotinib Metabolites (MSC2571109 and MSC2571107)
13300; 11000; 18100; 1120; 1120; 1050
SECONDARY
Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Tepotinib Metabolites (MSC2571109 and MSC2571107)
13400; 11100; 18500; 1130; 1140; 1080
SECONDARY
Maximum Observed Plasma Concentration (Cmax) of Tepotinib Metabolites (MSC2571109 and MSC2571107)
143; 132; 165; 13.9; 14.8; 10.1
SECONDARY
Time to Reach Maximum Observation Plasma Concentration (Tmax) of Tepotinib Metabolites (MSC2571109 and MSC2571107)
24.00; 24.00; 54.00; 24.00; 24.00; 30.00
SECONDARY
Apparent Terminal Half Life (t1/2) of Tepotinib Metabolites (MSC2571109 and MSC2571107)
46.3; 57.5; 78.8; 46.8; 40.7; 75.4
SECONDARY
Metabolite (MSC2571109 or MSC2571107) Area Under Curve From Time Zero Extrapolated To Infinity (AUC0-inf) to Tepotinib (AUC0-inf) Ratio
0.489; 0.424; 0.764; 0.0410; 0.0435; 0.0449
SECONDARY
Metabolite (MSC2571109 or MSC2571107) Maximum Observed Plasma Concentration Observed (Cmax) to Tepotinib Cmax Ratio
0.353; 0.318; 0.571; 0.0343; 0.0357; 0.0351
SECONDARY
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
1; 0; 2
SECONDARY
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters
0; 0; 0
SECONDARY
Number of Participants With Clinically Significant Changes From Baseline in Vital Signs and 12-lead Electrocardiogram (ECG) Findings
0; 0; 0; 0; 0; 0

Summary

The study investigated the effect of various degrees of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of tepotinib.

Eligibility Criteria

Inclusion Criteria

  • Men and women (of nonchildbearing potential), with a body mass index of 18 to 36 kilograms per meter square (inclusive) and a body weight greater than or equal to 50 kilograms at screening, with the absence of acute hepatitis or Human Immunodeficiency Virus 1 and 2, who gave informed consent and are willing and able to comply with study procedures were eligible for enrollment
  • Participants with impaired hepatic function (Child-Pugh class A or Child-Pugh class B) and participants with normal hepatic function were eligible to enroll in the study
  • Other protocol defined inclusion criteria could apply

Exclusion Criteria

  • Healthy participants were excluded if they have hepatitis B or C or had a previous infection with hepatitis C treated with Sofosbuvir or other antiviral compounds, or any other clinically relevant disease, as considered by the Investigator
  • Participants with impaired hepatic function were excluded if they have primary biliary liver cirrhosis, nonstabilized chronic heart failure, hepatocarcinoma, hepatic encephalopathy (Grade III or IV), sepsis or gastrointestinal bleeding, or any other clinically relevant disease, as considered by the Investigator
  • Other protocol defined exclusion criteria could apply
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03546608). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search